Première démonstration d'une supériorite des agents antihypertenseurs modernes par rapport aux molécules plus anciennes dans la prévention cardio-vasculaire : résultats du bras "abaissement de pression artérielle" de l'étude ASCOT
[en] In the antihypertensive population, a normalisation of blood pressure level must be the first objective. The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) - Blood Pressure lowering arm again confirms this assertion. The benefit has been proportional to the blood pressure decrease. However, the use of newest antihypertensive drugs (the long acting dihydropyridine calcium antagonist amlodipine very often associated to the ACE inhibitor perindopril) in the hypertensive population aged from 40 to 79 years with at least 3 additional risk factors showed significantly lower rates of cardiovascular and total mortalities, cardiovascular events, new diabetes or renal impairment as compared to the atenolol-based combination drug regimen (with thiazide as required). It should be noted that almost all the patients also received a low dose of a hypolipidemic drug, atorvastatin. Both arms (the statin arm and the arm using antihypertensive drugs) have yet been stopped, after 3 and 5 years, respectively related to the large beneficial effects noted with the new antihypertensive and statin treatments, although the primary endpoints (non fatal myocardial infarctival and fatal coronary heart disease) were not reached. This study raises many unsolved questions about the explanation for such benefits or the future management of the hypertensive people whose characteristics were very similar to those people frequently encountered in clinical practice. However, the present study emphasizes the considerable efficacy of a combination of amlodipine-perindopril and a low dose of statin. [fr] Chez le patient hypertendu, le dogme est que le contrôle parfait de la pression artérielle doit être l'objectif principal. L'étude ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) et son bras "abaissement de pression artérielle" ne le contrediront certainement pas. Cependant, le recours à un traitement moderne à base d'amlodipine (un antagoniste calcique dihydropyridine à longue durée d'action) le plus souvent en association avec un inhibiteur de l'enzyme de conversion, le périndopril chez des hypertendus âgés de 40 à 79 ans et présentant au moins 3 facteurs de risque supplémentaires a démontré un bénéfice en terme de mortalité totale et cardiovasculaire, de prévention d'accidents cardio-vasculaires et de survenue de diabète par rapport aux traitements plus anciens (bêta-bloquant et diurétique thiazide) en l'occurrence l'aténolol et le bendrofluméthiazide. Il faut remarquer que tous ces patients recevaient aussi une petite dose de statine (atorvastatine). Tant le bras hypolipémiant que celui étudiant les antihypertenseurs ont dû être interrompus au vu des bénéfices importants obtenus après respectivement 3,3 ans sous statine et 5 ans sous amlodipine ± périndopril, alors que l'objectif primaire n'était pas atteint. Cette étude soulève beaucoup de questions quant aux raisons de ces bénéfices, quant à la future prise en charge de l'hypertendu dont les caractéristiques dans cet essai étaient fort proches de la majorité des patients rencontrés en pratique quotidienne. En tout cas, chez ce genre de patientèle, l'association amlodipine, périndopril et faible dose de statine a été très efficace.
Krzesinski, Jean-Marie ; Université de Liège - ULiège > Département des sciences cliniques > Néphrologie
Language :
French
Title :
Première démonstration d'une supériorite des agents antihypertenseurs modernes par rapport aux molécules plus anciennes dans la prévention cardio-vasculaire : résultats du bras "abaissement de pression artérielle" de l'étude ASCOT
Alternative titles :
[en] First Evidence of Greater Cardiovascular Protective Effects of Newer as Compared to Old Antihypertensive Drugs Treatments: The Ascot-Bpla Results
Publication date :
October 2005
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
Staessen J, Wang J-G, Thijs L.- Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet, 2001, 358, 1305-1315.
Chobanian A, Bakris G, Black H, et al.- The JNC 7 Report - The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA, 2003, 289, 2560-2572.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).- Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA, 2002, 288, 2981-2997.
Scheen AJ, Krzesmski J-M.- Quel antihypertenseur en première intention? Résultats de l'étude ALLHAT. Rev Med Liège, 2003, 58, 47-52.
Dahlöf B, Devereux R, Kjeldsen S, et al.- Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 2002, 359, 995-1003.
Blood Pressure Lowering Treatment Trialists' Collaboration.-Effects of different blood-pressure regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet, 2003, 362, 1527-1535.
Verdecchia P, Reboldi G, Angeli F, et al.- Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension, 2005, 45, 386-392.
Sever P, Dahlöf B, Poulter N, et al.- Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. J Hypertens, 2001, 19, 1139-1147.
Sever P, Dahlöf B, Poulter N, et al.- Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet, 2003. 361, 1149-1158.
Scheen AJ.- Interruption prématurée des études ASCOT et CARDS de prévention cardio-vasculaire avec l'atorvastatine chez le sujet hypertendu ou diabétique: compromis entre éthique et statistique en médecine factuelle. Rev Med Liège, 2003, 58, 585-590.
Dahlöf G, Sever P, Poulter N, et al.- Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet, 2005, 366, 895-906.
The Prospectives Studies Collaboration.- Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet, 202, 360, 1903-1913.
Staessen J, Birkenhäger W.- Evidence that new antihypertensives are superior to older drugs. Lancet, 2005, 366, 869-871.
Guidelines Committee.- 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens, 2003, 21, 1011-1053.
Krzesinski J-M.- Actualisation de la prise en charge de l'hypertension artérielle. Rev Med Liège, 1999, 54, 683-687.
Institut National d'Assurance Maladie-Invalidité. La place des médicaments dans le traitement de l'hypertension. Folia Pharmacotherapeutica, 2001, (suppl.) 11, 3-7.
Centre Belge d'Information Pharmacothérapcutique.- Traitement initial de l'hypertension artérielle: état de la question. Folia Pharmacotherapeutica, 2004, 31, 28-32.
Collins R. Peto R, MacMahon S, et al.- Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet, 1990, 335, 827-838.
Poulter N, Wedel H, Dahlöf B, et al.- Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet, 2005, 366, 907-913.
Scheen AJ.- Reduction comparable des nouveaux cas de diabète de type 2 sous sartan et sous inhibiteur de l'enzyme de conversion de l'angiotensine: Comparaison des méta-analyses des essais prospectifs randomisés. Rev Med Liège, 2005, 60, 424-428.
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.